Evidence map›Paper›PMID 42741049›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Linking cognitive variability and Alzheimer's disease biomarkers by neurocognitive status.

Shayne S-H Lin, Alicia Milam, Andrew M Kiselica, Stephen L Aita, Mubarick Saeed, Troy Webber, Steven Paul Woods, Nicholas C Borgogna, Keenan A Walker, Vidyulata Kamath and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Cognitive dispersion profiles and prediction of cognitive change in early-onset dementias: Results from LEADS.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Shayne S-H LinDepartment of Neurosurgery Medical College of Wisconsin Milwaukee Wisconsin USA.
Alicia MilamMichael E. DeBakey Veterans Affairs Medical Center in Houston Houston Texas USA.
Andrew M KiselicaInstitute of Gerontology University of Georgia Athens Georgia USA.
Stephen L AitaDepartment of Neurology, Whiddon College of Medicine at the University of South Alabama Mobile Alabama USA.
Mubarick SaeedDepartment of Neurology Heersink School of Medicine University of Alabama at Birmingham Birmingham Alabama USA.
Troy WebberMichael E. DeBakey Veterans Affairs Medical Center in Houston Houston Texas USA.
Steven Paul WoodsDepartment of Psychology University of Houston Houston Texas USA.
Nicholas C BorgognaDepartment of Psychology University of Alabama at Birmingham Birmingham Alabama USA.
Keenan A WalkerLaboratory of Behavioral Neuroscience, Intramural Research Program National Institute of Aging Baltimore Maryland USA.
Vidyulata KamathDepartment of Psychiatry & Behavioral Science Johns Hopkins University School of Medicine Baltimore Maryland USA.
Kristina VisscherFrances Gorrie Alzheimer's Disease Center University of Alabama at Birmingham Birmingham Alabama USA.
Charles F MurchisonDepartment of Neurology Heersink School of Medicine University of Alabama at Birmingham Birmingham Alabama USA.
David S GeldmacherDepartment of Neurology Heersink School of Medicine University of Alabama at Birmingham Birmingham Alabama USA.
Erik D RobersonDepartment of Neurology Heersink School of Medicine University of Alabama at Birmingham Birmingham Alabama USA.
Benjamin D HillDepartment of Psychology University of South Alabama Mobile Alabama USA.
Victor A Del BeneDepartment of Neurology Heersink School of Medicine University of Alabama at Birmingham Birmingham Alabama USA.

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$120.9M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
The Clinical Significance of Incidental White Matter Lesions on MRI Amongst a Diverse Population with Cognitive Complaints (INDEED)U19NS120384 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Kumar B. Rajan · 2020 to 2026
$61.9M
Alzheimer's Disease Genetics ConsortiumU01AG032984 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SCHELLENBERG, GERARD DAVID · 2009 to 2024
$60.4M
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5M
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SWEET, ROBERT A · 1985 to 2019
$43.0M
NCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR002345NCRR NIH HHS U24 RR021382NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P20 AG068024NIA NIH HHS P20 AG068053NIA NIH HHS P20 AG068077NIA NIH HHS P20 AG068082NIA NIH HHS P30 AG008017NIA NIH HHS P30 AG010129NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG013846NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG035982NIA NIH HHS P30 AG053760NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062428NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066508NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066512NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072931NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072959NIA NIH HHS P30 AG072972NIA NIH HHS P30 AG072973NIA NIH HHS P30 AG072975NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072978NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG072980NIA NIH HHS P30 AG086401NIA NIH HHS P50 AG005133NIA NIH HHS P50 AG005136NIA NIH HHS P50 AG005142NIA NIH HHS P50 AG008702NIA NIH HHS P50 AG016573NIA NIH HHS P50 AG016574NIA NIH HHS P50 AG033514NIA NIH HHS P50 AG047266NIA NIH HHS P50 AG047270NIA NIH HHS P50 AG047366NIA NIH HHS R01 AG019771NIA NIH HHS R01 AG021910NIA NIH HHS R01 AG043434NIA NIH HHS R01 AG045571NIA NIH HHS R01 AG052560NIA NIH HHS R01 AG053509NIA NIH HHS R01 AG053993NIA NIH HHS R01 AG054110NIA NIH HHS R01 AG055005NIA NIH HHS R01 AG056031NIA NIH HHS R01 AG056258NIA NIH HHS R01 AG056531NIA NIH HHS R01 AG058724NIA NIH HHS R01 AG061788NIA NIH HHS R01 AG062276NIA NIH HHS R01 AG067781NIA NIH HHS R01 AG068338NIA NIH HHS R01 AG069453NIA NIH HHS R01 AG073235NIA NIH HHS R01 AG077444NIA NIH HHS R01 AG079280NIA NIH HHS R35 AG072262NIA NIH HHS R56 AG045571NIA NIH HHS R56 AG074321NIA NIH HHS RF1 AG085638NIA NIH HHS U01 AG032984NIA NIH HHS U01 AG057195NIA NIH HHS U19 AG063911NIA NIH HHS U19 AG073153NIA NIH HHS U24 AG067418NIA NIH HHS U24 AG072122NIBIB NIH HHS R01 EB009352NIDCD NIH HHS R01 DC008552NIH HHS S10 OD026738NIMH NIH HHS P50 MH071616NINDS NIH HHS P30 NS098577NINDS NIH HHS R01 NS075075NINDS NIH HHS U19 NS120384RRD VA I01 RX001534RRD VA I21 RX001381
6 · The paper itself

Abstract

introductionThis study aimed to assess intra-individual cognitive variability (IICV) in relation to Alzheimer's disease (AD) biomarkers.

methodsThe National Alzheimer's Coordinating Center sample (

resultsIncreased AD biomarker burden was associated with increased IICV among cognitively impaired individuals (correlational strength ranging from 0.149 to 0.460) but not among the cognitively intact group. DISCUSSION: Increases in measures of amyloid, soluble tau, and neurodegeneration are associated with increased IICV among cognitively impaired older adults. The findings underscore the potential of IICV as a sensitive outcome measure. Future studies should replicate findings longitudinally and in more diverse samples.

Indexed as

BiomarkersDementiaGeriatric MedicineMild Cognitive ImpairmentNeurologyNeuropsychology

Identifiers

PMID42741049
PMCPMC13572577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.